Proyecto CANTCAM (Carcinoma ANaplásico de Tiroides en CAstilla-La Mancha). Estudio retrospectivo multicéntrico

4区医学 Q3 Nursing

Endocrinologia, Diabetes y Nutricion Pub Date : 2025-06-01 DOI:10.1016/j.endinu.2025.501580

Sandra Herranz-Antolín , Rosa Quílez-Toboso , Jesús Moreno-Fernández , Javier González-López , María López-Iglesias , Julia Sastre

{"title":"Proyecto CANTCAM (Carcinoma ANaplásico de Tiroides en CAstilla-La Mancha). Estudio retrospectivo multicéntrico","authors":"Sandra Herranz-Antolín , Rosa Quílez-Toboso , Jesús Moreno-Fernández , Javier González-López , María López-Iglesias , Julia Sastre","doi":"10.1016/j.endinu.2025.501580","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To analyze the clinical presentation, diagnosis, management and survival of Anaplastic Thyroid Carcinomas (ATC) in the Hospitals of Castilla-La Mancha (Spain).</div></div><div><h3>Material and methods</h3><div>Retrospective multicenter descriptive study. Adult patients with ATC diagnosed from 2002 to 2022 were included.</div></div><div><h3>Results</h3><div>Of the 43 patients included, 53.5% were women, with a mean age of 72 years (SD 10) at the time of diagnosis. Symptoms were present in 100% of the patients and the most frequent symptom was a rapidly growing mass (79.1% of the cases). Infiltration of neighboring structures (76.7%), lymph node involvement (78.1%) and distant metastasis (51.2%). The AJCC-TNM category was IVa in 9.3%, IVb in 39.5% and IVc in 51.2%. <em>BRAF</em><sup><em>V600E</em></sup> determination was not performed in 74.4% and 5 of the 11 cases in which it was evaluated (45.4%) had the mutation. Active treatment was received in 76.7% of patients in the first 3 months. Surgical approach was performed in 63.6% of the cases, with complete resection in 23.8%, and 51.5% received multimodality treatment in this period. 42.3% received active treatment during follow-up (≥3 months), primarily systemic chemotherapy (72.7%), and 54.4% received multimodality treatment during this period. The median specific survival was 3.5 months (95% CI 1.7-5.2). Factors associated with longer specific survival were initial multimodality treatment (p<0.01) or during follow-up (p=0.01) and initial BRAF/MEK inhibitor treatment (p=0.04).</div></div><div><h3>Conclusion</h3><div>CAT is an infrequent and aggressive tumor that requires early, multidisciplinary, personalized and multimodal treatment.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"72 6","pages":"Article 501580"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinologia, Diabetes y Nutricion","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2530016425000412","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Nursing","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To analyze the clinical presentation, diagnosis, management and survival of Anaplastic Thyroid Carcinomas (ATC) in the Hospitals of Castilla-La Mancha (Spain).

Material and methods

Retrospective multicenter descriptive study. Adult patients with ATC diagnosed from 2002 to 2022 were included.

Results

Of the 43 patients included, 53.5% were women, with a mean age of 72 years (SD 10) at the time of diagnosis. Symptoms were present in 100% of the patients and the most frequent symptom was a rapidly growing mass (79.1% of the cases). Infiltration of neighboring structures (76.7%), lymph node involvement (78.1%) and distant metastasis (51.2%). The AJCC-TNM category was IVa in 9.3%, IVb in 39.5% and IVc in 51.2%. BRAF^V600E determination was not performed in 74.4% and 5 of the 11 cases in which it was evaluated (45.4%) had the mutation. Active treatment was received in 76.7% of patients in the first 3 months. Surgical approach was performed in 63.6% of the cases, with complete resection in 23.8%, and 51.5% received multimodality treatment in this period. 42.3% received active treatment during follow-up (≥ 3 months), primarily systemic chemotherapy (72.7%), and 54.4% received multimodality treatment during this period. The median specific survival was 3.5 months (95% CI 1.7-5.2). Factors associated with longer specific survival were initial multimodality treatment (p < 0.01) or during follow-up (p = 0.01) and initial BRAF/MEK inhibitor treatment (p = 0.04).

Conclusion

CAT is an infrequent and aggressive tumor that requires early, multidisciplinary, personalized and multimodal treatment.

查看原文本刊更多论文

CANTCAM项目（卡斯蒂利亚-拉曼查甲状腺间变性癌）。多中心回顾研究

目的分析西班牙卡斯蒂利亚-拉曼查医院甲状腺间变性癌（ATC）的临床表现、诊断、治疗及生存情况。材料与方法回顾性多中心描述性研究。纳入了2002年至2022年诊断为ATC的成年患者。结果纳入的43例患者中，53.5%为女性，诊断时平均年龄为72岁（SD 10）。100%的患者出现症状，最常见的症状是快速增长的肿块（79.1%的病例）。邻近组织浸润（76.7%）、淋巴结受累（78.1%）和远处转移（51.2%）。AJCC-TNM分类中IVa占9.3%，IVb占39.5%，IVc占51.2%。74.4%的患者未进行BRAFV600E检测，11例患者中有5例（45.4%）存在突变。76.7%的患者在前3个月接受了积极治疗。63.6%的病例行手术入路，23.8%的病例行完全切除，51.5%的病例在此期间接受了多模式治疗。42.3%的人在随访期间（≥3个月）接受了积极治疗，主要是全身化疗（72.7%），54.4%的人在此期间接受了多模式治疗。中位特异性生存期为3.5个月（95% CI 1.7-5.2）。与更长的特异性生存期相关的因素是初始多模式治疗(p <；0.01)或随访期间（p = 0.01）和初始BRAF/MEK抑制剂治疗期间（p = 0.04）。结论cat是一种罕见的侵袭性肿瘤，需要早期、多学科、个性化、多模式治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrinologia, Diabetes y Nutricion Nursing-Nutrition and Dietetics

CiteScore

2.10

自引率

0.00%

发文量

169

审稿时长

35 days

期刊介绍： Endocrinología, Diabetes y Nutrición is the official journal of the Spanish Society of Endocrinology and Nutrition (Sociedad Española de Endocrinología y Nutrición, SEEN) and the Spanish Society of Diabetes (Sociedad Española de Diabetes, SED), and was founded in 1954. The aim of the journal is to improve knowledge and be a useful tool in practice for clinical and laboratory specialists, trainee physicians, researchers, and nurses interested in endocrinology, diabetes, nutrition and related disciplines. It is an international journal published in Spanish (print and online) and English (online), covering different fields of endocrinology and metabolism, including diabetes, obesity, and nutrition disorders, as well as the most relevant research produced mainly in Spanish language territories. The quality of the contents is ensured by a prestigious national and international board, and by a selected panel of specialists involved in a rigorous peer review. The result is that only manuscripts containing high quality research and with utmost interest for clinicians and professionals related in the field are published. The Journal publishes Original clinical and research articles, Reviews, Special articles, Clinical Guidelines, Position Statements from both societies and Letters to the editor. Endocrinología, Diabetes y Nutrición can be found at Science Citation Index Expanded, Medline/PubMed and SCOPUS.